Oncotelic Therapeutics Inc logo

Oncotelic Therapeutics Inc

$ 0.07 +0.008 (+12.9%) 10:08 PM EST
P/E:
3.33
P/B:
1.11
Market Cap:
$ 27.00M
Enterprise V:
$ 36.40M
Volume:
115.01K
Avg Vol (2M):
193.59K
Also Trade In:
Volume:
115.01K
Market Cap $:
27.00M
PE Ratio:
3.33
Avg Vol (2-Month):
193.59K
Enterprise Value $:
36.40M
PB Ratio:
1.11
GF Score:
Year:
Embed
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
Oncotelic Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer with a focus on rare pediatric cancers, and addressing the current global pandemic. OT-101 is its lead immuno-oncology drug candidate. OT-101 also has activity against SARS-CoV-2. Its other products under pipeline are Artemisinin, CA4P, and Oxi4503. Currently, the company generates revenues from rendering services to other third-party customers for the development of certain drug products or in connection with certain out-licensing agreements.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt 0.04
Equity-to-Asset 0.6
Debt-to-Equity 0.4
Debt-to-EBITDA -1.26
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0
Distress
Grey
Safe
Beneish M-Score -4.03
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate 29.8
3-Year EPS without NRI Growth Rate 24.6
3-Year FCF Growth Rate 41.8

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 48.83
9-Day RSI 41.54
14-Day RSI 38.29
6-1 Month Momentum % -64.76
12-1 Month Momentum % -34.6

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.03
Quick Ratio 0.03
Cash Ratio 0.02

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -108.5

Profitability Rank

Name Current Vs Industry Vs History
ROE % 70.19
ROA % 29.12
ROIC % -20.94
ROC (Joel Greenblatt) % -146775
ROCE % -68.99

Financials

OTLC's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with OTCPK:OTLC

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Embed

Valuation Box

Year:
Embed

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0
EPS (TTM) ($) 0.021
Beta -0.33
Volatility % 82.34
14-Day RSI 38.29
14-Day ATR ($) 0.004991
20-Day SMA ($) 0.075741
12-1 Month Momentum % -34.6
52-Week Range ($) 0.061 - 0.259
Shares Outstanding (Mil) 385.72

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Oncotelic Therapeutics Inc Filings

Document Form Filing Date
No Filing Data

Oncotelic Therapeutics Inc Analysis

Share your research

Headlines

See More
No news.